Nectar Lifesciences CGST case remanded for fresh consideration

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • The Hon'ble High Court of Punjab and Haryana remanded a CGST dispute involving Nectar Lifesciences back to the Appellate Authority for fresh consideration on September 24, 2026
  • The Principal Commissioner of CGST Commissionerate, Ludhiana, filed a civil writ petition challenging the Appellate Authority's order dated May 27, 2025
  • The earlier appellate order had dropped a ₹89.32 crore demand and remanded a ₹6.24 crore demand for de novo adjudication
  • The Appellate Authority had confirmed ineligible ITC of ₹17.06 lakh (CGST ₹8.53 lakh and SGST ₹8.53 lakh) with an equivalent penalty
  • The company states the final quantum of liability is presently not ascertainable and reserves the right to appeal before the Hon'ble Tribunal if required
powered bylight_fuzz_icon
52570535

*this image is generated using AI for illustrative purposes only.

Nectar Lifesciences Limited disclosed on October 3, 2026, that the Hon'ble High Court of Punjab and Haryana remanded a Central Goods and Services Tax (CGST) dispute back to the Appellate Authority for fresh consideration, with a potential financial exposure of up to ₹89.32 crore plus interest and penalties.

Background of the CGST dispute

The Commissioner (Appeal), acting as the Appellate Authority, had passed an order dated May 27, 2025, in a matter involving Nectar Lifesciences. The Appellate Authority's order addressed multiple demands and penalties raised by the Principal Commissioner of CGST Commissionerate, Ludhiana, Punjab. The key outcomes of that appellate order are summarised below.

Matter Appellate authority's order (May 27, 2025)
Ineligible Input Tax Credit (ITC) Confirmed ₹17.06 lakh (CGST ₹8.53 lakh and SGST ₹8.53 lakh) with equivalent penalty
Balance demand Dropped ₹89.32 crore along with applicable interest and penalties
Separate demand Remanded ₹6.24 crore to proper officer for de novo adjudication with adjustment of taxes/interest already paid
Personal penalties Quashed ₹25,000 each imposed on Sanjiv Goyal (Chairman and Managing Director), R. K. Aggarwal, and Sandeep Goel (former employees)

Writ petition and high court order

Following the Appellate Authority's order, the Principal Commissioner of CGST Commissionerate, Ludhiana, filed a civil writ petition before the Hon'ble High Court of Punjab and Haryana, challenging the appellate order. The writ petition sought, among other reliefs:

  • An appropriate writ order quashing and setting aside the impugned order
  • Directions restoring the Order-in-Original that was quashed in the impugned order
  • An interim stay on the operation of the impugned order

The Hon'ble High Court of Punjab and Haryana, vide its order dated September 24, 2026, remanded the matter back to the Appellate Authority for fresh consideration.

Financial implication for the company

Nectar Lifesciences stated that in the event the Appellate Authority reconsiders the matter, the company may be exposed to the following financial liabilities:

Potential liability Amount
Demand (with interest and penalties) ₹89.32 crore
Separate remanded demand ₹6.24 crore

The company noted that the final quantum of liability is presently not ascertainable. Nectar Lifesciences also stated that it reserves the right to prefer an appeal before the Hon'ble Tribunal, if required. The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the related SEBI Master Circular.

Historical Stock Returns for Nectar Lifesciences

1 Day5 Days1 Month6 Months1 Year5 Years
-2.57%-7.50%-17.96%+10.00%-28.96%-65.20%

How might the potential ₹95.56 crore liability impact Nectar Lifesciences' working capital and liquidity ratios in the upcoming fiscal quarters?

Will the remand to the Appellate Authority trigger a re-evaluation of the company's credit ratings by major agencies due to increased contingent liabilities?

What is the likelihood of Nectar Lifesciences pursuing further litigation at the Tribunal level, and how could this extend the timeline for financial resolution?

Nectar Lifesciences corrects AGM cut-off date error in revised proceedings

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Nectar Lifesciences issued revised AGM proceedings to correct a cut-off date error
  • Shareholders approved FY26 financials and reappointed key board members
  • Promoter group voted 100% in favour of all five resolutions
  • Statutory auditors gave unqualified opinion on FY25-26 results
powered bylight_fuzz_icon
51260591

*this image is generated using AI for illustrative purposes only.

Nectar Lifesciences has issued revised proceedings for its 31st annual general meeting (AGM) held on September 18, 2026. The update corrects an inadvertent error regarding the cut-off date for voting eligibility. Shareholders had previously approved the company’s standalone and consolidated financial statements for FY26 during the meeting.

The revised disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary Sanjaymohan Singh Rawat signed the letter dated September 19, 2026, enclosing the corrected proceedings. The original cut-off date for voting eligibility is confirmed as Friday, September 11, 2026.

Voting Results

The Consolidated Scrutinizer's Report confirmed that all five resolutions passed with the requisite majority. A total of 133 members cast their votes through remote e-voting and instant polling during the AGM. The promoter group, holding 100,706,448 shares (51.84% of total shares), voted 100% in favour of all resolutions.

Resolution Votes Polled In Favour Against % In Favour
Adoption of Financial Statements 101,660,738 101,646,467 14,271 99.99%
Reappointment of Sanjiv Goyal 101,660,738 101,626,376 34,362 99.97%
Reappointment of Dr. Kuldip Kumar Bhasin 101,660,738 101,626,376 34,362 99.97%
Reappointment of Dr. Indu Pal Kaur 101,660,738 101,626,376 34,362 99.97%
Appointment of Dr. Gunmala Suri 101,660,738 101,626,376 34,362 99.97%

Public institutional investors also voted unanimously in favour of all resolutions. Among public non-institutional investors, support ranged from 46.82% to 77.91% depending on the resolution, though the promoter block ensured passage in all cases.

Audit and Governance

Statutory auditors M/s. Deepak Jindal & Co., Chartered Accountants, and secretarial auditors P. Chadha & Associates expressed an unqualified opinion on the financial year 2025-26 results. No qualifications or adverse comments were noted in the audit reports regarding the company’s functioning or financial statements.

Board Appointments

The following resolutions were passed during the ordinary and special business segments:

Director Role Action
Sanjiv Goyal Chairman & Managing Director Reappointed by rotation
Dr. Kuldip Kumar Bhasin Independent Director Reappointed for second term
Dr. Indu Pal Kaur Independent Director Reappointed for second term
Dr. Gunmala Suri Non-Executive Non-Independent Director Appointed

Chairman Sanjiv Goyal thanked members for their trust and acknowledged the commitment of the company’s workforce. The meeting concluded at 11:25 am.

Historical Stock Returns for Nectar Lifesciences

1 Day5 Days1 Month6 Months1 Year5 Years
-2.57%-7.50%-17.96%+10.00%-28.96%-65.20%

How might the reappointment of key directors and the addition of Dr. Gunmala Suri influence Nectar Lifesciences' strategic direction for FY27?

What specific growth initiatives or R&D projects are likely to be prioritized following the unqualified audit opinion and approval of FY26 financials?

Could the variance in voting support among public non-institutional investors (46.82% to 77.91%) signal emerging concerns about corporate governance or dividend policy?

More News on Nectar Lifesciences

1 Year Returns:-28.96%